NVCR NovoCure Ltd

Price (delayed)

$164.55

Market cap

$16.75B

P/E Ratio

822.75

Dividend/share

N/A

EPS

$0.2

Enterprise value

$16.53B

Sector: Healthcare
Industry: Medical Instruments & Supplies

Highlights

The net income has soared by 171% YoY and by 62% from the previous quarter
NVCR's EPS has surged by 169% year-on-year and by 54% since the previous quarter
The company's quick ratio fell by 31% QoQ and by 21% YoY

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
101.8M
Market cap
$16.75B
Enterprise value
$16.53B
Valuations
Price to earnings (P/E)
822.75
Price to book (P/B)
54.18
Price to sales (P/S)
37.05
EV/EBIT
895.27
EV/EBITDA
598.73
EV/Sales
36.76
Earnings
Revenue
$449.65M
EBIT
$18.46M
EBITDA
$27.61M
Free cash flow
$40.37M
Per share
EPS
$0.2
Free cash flow per share
$0.4
Book value per share
$3.04
Revenue per share
$4.44
TBVPS
$4.26
Balance sheet
Total assets
$431.05M
Total liabilities
$124.01M
Debt
$13.08M
Equity
$307.04M
Working capital
$288.15M
Liquidity
Debt to equity
0.04
Current ratio
4.02
Quick ratio
3.74
Net debt/EBITDA
-8.05
Margins
EBITDA margin
6.1%
Gross margin
77.1%
Net margin
4.3%
Operating margin
4.1%
Efficiency
Return on assets
3.9%
Return on equity
7.4%
Return on invested capital
5.7%
Return on capital employed
5.5%
Return on sales
4.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
0%
1 week
-4.54%
1 month
-4.31%
1 year
89.14%
YTD
-4.91%
QTD
-4.91%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$449.65M
Gross profit
$346.5M
Operating income
$18.46M
Net income
$19.15M
Gross margin
77.1%
Net margin
4.3%
The net income has soared by 171% YoY and by 62% from the previous quarter
NovoCure's operating income has surged by 153% QoQ
NovoCure's net margin has soared by 151% YoY and by 48% from the previous quarter
NovoCure's operating margin has surged by 128% QoQ

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
822.75
P/B
54.18
P/S
37.05
EV/EBIT
895.27
EV/EBITDA
598.73
EV/Sales
36.76
NVCR's EPS has surged by 169% year-on-year and by 54% since the previous quarter
The price to book (P/B) is 144% higher than the 5-year quarterly average of 22.2 and 74% higher than the last 4 quarters average of 31.2
The equity has surged by 61% year-on-year and by 15% since the previous quarter
NVCR's price to sales (P/S) is 130% higher than its 5-year quarterly average of 16.1 and 83% higher than its last 4 quarters average of 20.2
The company's revenue rose by 40% YoY and by 10% QoQ

Efficiency

How efficient is NovoCure business performance
NovoCure's ROIC has soared by 200% from the previous quarter
The company's return on assets has surged by 156% YoY and by 63% QoQ
NovoCure's return on equity has surged by 140% YoY and by 45% QoQ
NVCR's return on sales has surged by 128% since the previous quarter

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total liabilities has shrunk by 53% QoQ and by 51% YoY
The company's quick ratio fell by 31% QoQ and by 21% YoY
NovoCure's debt is 96% less than its equity
NVCR's debt to equity has shrunk by 95% YoY and by 93% QoQ
NovoCure's debt has plunged by 92% from the previous quarter and by 92% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.